Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage StudyBenzinga • 05/12/20
This Biotech Just Lost Half Its Value After A Key Hepatitis Drug FailedInvestors Business Daily • 05/11/20